




The Valentines Trial

DIOR® drug-eluting balloon treatment of ISR



The Valentines Trial

DIOR® drug-eluting balloon treatment of ISR



- first of it's kind
- 330 physicians from 265 cath labs and 32 countries
- unrivaled global ISR treatment database with DEB



The Valentines Trial

DIOR® drug-eluting balloon treatment of ISR



Patient Data

- 265 lesions in 250 patients
- Gender (77.2% male)
- Age (61.7 ± 10.1)
- Diabetes mellitus (31.6%)
- Hypertension (80.4%)
- Hyperlipidemia (60.4%)
- Smoking (23.2%)
- Previous MI (46.4%)
- Clinical presentation (56.8% stable angina; 32.8% unstable angina)
- Follow-up (97.6% at 228 ± 44 days)
- On-site monitoring (56%)

Characteristics of ISR lesions (265)


- BMS-ISR (63.4%)
- DES-ISR (32.8%)
- Covered Stent-ISR (0.4%)
- Unknown stent type (3.4%)

Conclusion

- Safe
- Efficient
- Globally proven
- Recommended for BMS-ISR and DES-ISR


Submissions

More than 56% on site monitoring



Enrollment


During "working days":
inclusion rate of 1 patient per hour



Monitoring


■ No of pts. screened
■ No of pts. accepted

Overall Follow up Outcomes




¹ MACE is defined as, all cause death, MI, TVR and ST

BMS-ISR vs. DES-ISR – Follow up Outcomes



Overall Diabetic (DM) vs. Non-Diabetic (Non-DM) Follow up Outcomes



Principal Investigators

Prof. Dr. Giuseppe Sangiorgi (Modena, Italy); Prof. Dr. Sigmund Silber (Munich, Germany); Prof. Dr. Pieter R. Stella (Utrecht, Netherlands)

